Avalo Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2025: 67.67%

Avalo Therapeutics Inc (AVTX) has an Asset Resilience Ratio of 67.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AVTX capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$84.65 Million

Cash + Short-term Investments

Total Assets

$125.10 Million

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2019–2020)

This chart shows how Avalo Therapeutics Inc's Asset Resilience Ratio has changed over time. See Avalo Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Avalo Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Avalo Therapeutics Inc worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$84.65 Million	67.67%
Total Liquid Assets	$84.65 Million	67.67%

Asset Resilience Insights

Very High Liquidity: Avalo Therapeutics Inc maintains exceptional liquid asset reserves at 67.67% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Avalo Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Avalo Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Avalo Therapeutics Inc (2019–2020)

The table below shows the annual Asset Resilience Ratio data for Avalo Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2020-12-31	0.00%	$0.00	$43.76 Million	--
2019-12-31	21.13%	$7.63 Million	$36.11 Million	--

pp = percentage points

About Avalo Therapeutics Inc

NASDAQ:AVTX USA Biotechnology

Market Cap

$285.10 Million

Market Cap Rank

#15184 Global

#3535 in USA

Share Price

$15.40

Change (1 day)

+7.47%

52-Week Range

$4.64 - $22.87

All Time High

$20793.60